Citius Oncology (CTOR) Income towards Parent Company (2023 - 2026)

Citius Oncology (CTOR) has 4 years of Income towards Parent Company data on file, last reported at -$26.6 million in Q1 2026.

• On a quarterly basis, Income towards Parent Company fell 243.99% year-over-year to -$26.6 million in Q1 2026; TTM through Mar 2026 was -$42.5 million, a 47.96% decrease from a year earlier, with the FY2025 full-year figure at -$24.8 million, down 17.08% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$26.6 million, down from -$5.5 million in the prior quarter.
• Over the last five years, Income towards Parent Company for CTOR reached as high as -$147922.0 in Q1 2023 and fell as low as -$26.6 million in Q1 2026.
• Historically, Income towards Parent Company has averaged -$7.6 million across 4 years, with a median of -$5.5 million in 2025.
• Across the five-year window, Income towards Parent Company tumbled 7083.92% in 2024 and jumped 62.54% in 2025, its largest moves.
• Year by year, Income towards Parent Company stood at -$4.7 million in 2023, then plunged by 40.86% to -$6.7 million in 2024, then grew by 16.9% to -$5.5 million in 2025, then tumbled by 380.83% to -$26.6 million in 2026.
• Per Business Quant data, the three most recent Income towards Parent Company figures were -$26.6 million in Q1 2026, -$5.5 million in Q4 2025, and -$5.0 million in Q3 2025.